Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BeyondSpring Inc

BYSI
Current price
2.84 USD +0.05 USD (+1.79%)
Last closed 2.8 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 114 453 136 USD
Yield for 12 month +121.88 %
1Y
3Y
5Y
10Y
15Y
BYSI
21.11.2021 - 28.11.2021

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. Address: 28 Liberty Street, New York, NY, United States, 10005

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.25 USD

P/E ratio

Dividend Yield

Current Year

+1 751 000 USD

Last Year

+1 351 000 USD

Current Quarter

+438 000 USD

Last Quarter

+437 500 USD

Current Year

+1 751 000 USD

Last Year

+1 351 000 USD

Current Quarter

+438 000 USD

Last Quarter

+437 500 USD

Key Figures BYSI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -22 812 000 USD
Operating Margin TTM -1099.32 %
PE Ratio
Return On Assets TTM -40.68 %
PEG Ratio
Return On Equity TTM -310.48 %
Wall Street Target Price 1.25 USD
Revenue TTM 1 751 000 USD
Book Value -0.69 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 29.8 %
Dividend Yield
Gross Profit TTM 1 351 000 USD
Earnings per share -0.54 USD
Diluted Eps TTM -0.54 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BYSI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BYSI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BYSI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 10.5374
Enterprise Value Revenue 45.8126
Price Sales TTM 52.608
Enterprise Value EBITDA -2.4061
Price Book MRQ 5.3811

Financials BYSI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BYSI

For 52 weeks

0.65 USD 4 USD
50 Day MA 2.42 USD
Shares Short Prior Month 2 348 788
200 Day MA 1.58 USD
Short Ratio 50.2
Shares Short 2 342 755
Short Percent 9.87 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics